Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,979 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00072722 | Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC) | completed | Phase 2 | 36 | Celgene CorporationINDUSTRY | 1 | Dec 19, 2006 | clinicaltrials |
| NCT00132756 | Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 30 | Morton Plant Mease Health CareOTHER | 1 | Nov 8, 2006 | clinicaltrials |
| NCT00100243 | Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy | completed | Phase 2 | 22 | PRAECIS Pharmaceuticals Inc.INDUSTRY | 1 | Sep 19, 2006 | clinicaltrials |
| NCT00127088 | Study of Peri-Operative Docetaxel Plus Laparoscopic Radical Prostatectomy in Prostate Cancer Patients | suspended | Phase 2 | 37 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 11, 2006 | clinicaltrials |
| NCT00188383 | Effects of N-Methyl-D-Aspartate (NMDA)-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy | unknown | Phase 1 / Phase 2 | 132 | University Health Network, TorontoOTHER | 1 | Mar 14, 2006 | clinicaltrials |
| NCT00103428 | Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 69 | Cell GenesysINDUSTRY | 1 | Feb 2, 2006 | clinicaltrials |
| NCT00179738 | A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer. | terminated | Phase 2 | 40 | Celgene CorporationINDUSTRY | 1 | Nov 23, 2005 | clinicaltrials |
| NCT00215345 | A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer | unknown | Phase 2 | 66 | Department of Veterans Affairs, New JerseyFED | 1 | Sep 22, 2005 | clinicaltrials |
| NCT00218205 | A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer | unknown | Phase 2 | 28 | Department of Veterans Affairs, New JerseyFED | 1 | Sep 22, 2005 | clinicaltrials |
| NCT00164437 | CD-ROM Intervention for Prostate Cancer Screening | completed | Phase 2 / Phase 3 | 554 | Centers for Disease Control and PreventionFED | 1 | Sep 14, 2005 | clinicaltrials |
| NCT00140374 | Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer) | completed | Phase 1 / Phase 2 | 36 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00140387 | Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®) | completed | Phase 1 / Phase 2 | 20 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00140400 | Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 50 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00116155 | Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | — | Cell GenesysINDUSTRY | 0 | Jun 28, 2005 | clinicaltrials |
| NCT00061126 | ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body | completed | Phase 2 | 50 | AbgenixINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Dec 19, 2006source: clinicaltrials